Loading stock data…
ATHE
$4.82-0.08 (-1.63%)
Market ClosedLast close Jun 26
Alterity Therapeutics Limited is engages in research and development of Parkinsonian and neurodegenerative disorders, including Multiple System Atrophy (MSA) and Parkinson's disease.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Alterity Therapeutics Limited in the Healthcare sector is trading at $4.82 with a market capitalization of $80M. Wall Street consensus targets $11.00 (2 analysts), implying a +128.2% move over the next 12 months. The stock is currently 31% below its 52-week high of $7.00, remaining 23.9% above its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +128.2% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q2 2025 | Q1 2025 | Q4 2024 |
|---|---|---|---|---|---|
| Total Revenue | — | — | — | — | — |
| Gross Profit | — | — | — | — | — |
| Operating Income | — | — | — | — | — |
| Net Income | — | — | — | — | — |
Peer Comparison
JNJUNHPFE
Fundamentals
Alterity Therapeutics Limited is engages in research and development of Parkinsonian and neurodegenerative disorders, including Multiple System Atrophy (MSA) and Parkinson's disease. The company's lead drug candidate is ATH434, a small molecule drug ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$79.57M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-
Volume
Today's trading volume
23,412
Recent News
Is Allarity Therapeutics, Inc. (ALLR) Outperforming Other Medical Stocks This Year?
Here is how Allarity Therapeutics, Inc. (ALLR) and Alterity Therapeutics Limited - Sponsored ADR (ATHE) have performed compared to their sector so far this year.
Alterity Therapeutics Limited's (ASX:ATH) Path To Profitability
With the business potentially at an important milestone, we thought we'd take a closer look at Alterity Therapeutics...
Alterity Says Data Showed Potential Multiple System Atrophy Drug Slowed Disease Progression in Phase 2 Study
Alterity Therapeutics (ATHE) said Thursday that data from a 77-patient phase 2 clinical trial of its
Alterity Therapeutics (ATHE) Presents Positive Phase 2 Data for ATH434
Alterity Therapeutics Limited (NASDAQ:ATHE) is one of the best performing ASX stocks in 2025. On September 15, the company shared data from its Phase 2 clinical trial of the drug ATH434-201 at the American Neurological Association Annual Meeting in Baltimore. The clinical trial involved people with Multiple System Atrophy (MSA), a rare brain condition that […]
We Think Alterity Therapeutics (ASX:ATH) Can Easily Afford To Drive Business Growth
Just because a business does not make any money, does not mean that the stock will go down. For example, Alterity...